0000000000662680

AUTHOR

Salvatore Provenzano

showing 12 related works from this author

Expression of Cyclooxygenase-1 and Cyclooxygenase-2 in normal and pathological human oral mucosa

2011

Abstract: Cyclooxigenase (COX) is the rate-limiting enzyme for the conversion of arachidonic acid (AA) to prostaglandins (PGs). Two isoforms of COX have been identified: COX-1 is constitutively expressed in many cells and is involved in cell homeostasis, angiogenesis and cell-cell signalling; COX-2 is not expressed in normal condition however it is strongly expressed in inflammation. The oral cavity is costantly exposed to physical and chemical trauma that could lead to mucosal reactions such as hyperplasia, dysplasia and cancer. Early diagnosis is the most important issue to address for a positive outcome of oral cancer; therefore it would be useful to identify molecular markers whose expr…

Settore BIO/17 - IstologiaPathologymedicine.medical_specialtyHistologyAngiogenesiscarcinoma.Settore MED/29 - Chirurgia MaxillofaccialePathology and Forensic MedicinedysplasiaSettore MED/28 - Malattie OdontostomatologichemedicineCarcinomaHumanslcsh:QH573-671Oral mucosahuman oral mucosaNeoplasm StagingMouth neoplasmbiologyReverse Transcriptase Polymerase Chain Reactionlcsh:CytologyMouth MucosahyperplasiaCancerGeneral MedicineHyperplasiamedicine.diseaseImmunohistochemistryGene Expression Regulation Neoplasticmedicine.anatomical_structurecyclooxigenasesCyclooxygenase 2DysplasiaCyclooxygenase 1biology.proteinMouth NeoplasmsCyclooxygenasecyclooxigenases human oral mucosa hyperplasia dysplasia carcinomaPrecancerous Conditions
researchProduct

Systemic Treatment in Advanced Phyllodes Tumor of the Breast: A Multi-institutional European Retrospective Case-series Analyses

2022

Abstract Background: We aimed at investigating outcome of systemic treatments in advanced breast PT. Methods: All cases of advanced breast PT treated with systemic treatments from 1999 to 2019, in one of the referral sarcoma centres involved in the study, were retrospectively reviewed. Results: 56 female patients were identified. Median age was 52 (range 25-76) years. Patients re-ceived a median number of 2 systemic treatments (range 1-4). Best responses according to RECIST were: 1 (3.7%) CR, 11 (40.7%) PR, 6 (22.2%) SD, 9 (33.3%) PD with anthracyclines plus ifosfamide (AI); 2 (16.7%) PR, 4 (33.3%) SD, 6 (50.0%) PD with anthracycline alone; 3 (18.8%) PR, 4 (25.0%) SD, 9 (56.3%) PD with high…

AdultOncologyCancer Researchmedicine.medical_specialtyAdvanced setting; Breast tumor; Chemotherapy; Phyllodes; SarcomaBreast tumorBreast NeoplasmsAdvanced settingInternal medicineAntineoplastic Combined Chemotherapy ProtocolsHumansMedicineChemotherapyResponse Evaluation Criteria in Solid TumorsAgedRetrospective StudiesSeries (stratigraphy)business.industryPhyllodes tumorPhyllodesSarcomaMiddle Agedmedicine.diseaseOncologyFemalebusiness
researchProduct

MMP-2, MMP-9, and iNOS Expression in Human Dental Pulp Subjected to Orthodontic Traction

2009

Abstract Objective: To test the hypothesis that some metalloproteinases (MMP-2, MMP-9) and inducible nitric oxide synthetase (iNOS) enzymes in dental pulp samples do not vary when subjected to orthodontic treatment. Materials and Methods: Human dental pulps were taken from male and female patients (N=10; age 10–14 years). A straight wire technique was used with nickel-titanium or steel archwires. The increase of pressure applied on teeth was gradual. Five patients were subjected to premolar extractions after 14 months of treatment and one after 24 months. Samples were Bouin-fixed, paraffin-embedded, and afterwards processed for immunohistochemistry using anti-MMP-2, anti-MMP-9, and anti-iNO…

MaleSettore BIO/17 - IstologiaTime FactorsNitric oxide synthetaseAdolescentTooth Movement TechniquesNitric Oxide Synthase Type IIDentistryOrthodonticsMalocclusion Angle Class IIMatrix metalloproteinaseNickelFemale patientOrthodontic WiresPressurePremolarHumansMedicineBicuspidChildTitaniumOdontoblastsMMP-2Orthodontic wirebusiness.industrymedicine.diseaseImmunohistochemistryBiomechanical PhenomenaDental pulpiNOSmedicine.anatomical_structureMatrix Metalloproteinase 9SteelMatrix Metalloproteinase 2ImmunohistochemistryFemaleStress MechanicalTreatment timeMalocclusionMMP-9businessImmunohistochemistry Dental pulp MMP-2 MMP-9 iNOS.Dental AlloysFollow-Up StudiesThe Angle Orthodontist
researchProduct

Familial adenomatosis polyposis-related desmoid tumours treated with low-dose chemotherapy: Results from an international, multi-institutional, retro…

2019

[Introduction] Desmoid tumour (DT) is a locally aggressive fibroblastic proliferative disease representing the most common extraintestinal manifestation of familial adenomatosis polyposis (FAP). As data on the activity of chemotherapy in these patients are limited, we examined the outcomes of patients treated with low-dose methotrexate (MTX)+vinca alkaloids (vinorelbine or vinblastine).

Adultfamilial adenomatosis polyposiCancer Researchmedicine.medical_specialtyVincaAdolescentVinca alkaloidsdesmoidmedicine.medical_treatmentPopulationVinorelbinechemotherapyGastroenterologymethotrexatevinca alkaloidsYoung Adultchemotherapy; desmoid; familial adenomatosis polyposis; methotrexate; vinca alkaloidsLow-dose chemotherapyInternal medicinemedicineHumansChemotherapyChildeducationDesmoidSurvival analysisRetrospective StudiesChemotherapyeducation.field_of_studybiologybusiness.industryFamilial adenomatosis polyposisbiology.organism_classificationmedicine.diseasefamilial adenomatosis polyposisMethotrexateAdenomatous Polyposis ColiOncologyFemaleSarcomabusinessProgressive diseasemedicine.drug
researchProduct

Assessment of gutta-percha adaptation with different root canal obturation techniques.

2010

Materials scienceRoot Canal ObturationbiologySettore MED/28 - Malattie OdontostomatologicheMechanics of Materialsbusiness.industryDentistryGeneral Materials ScienceGutta-perchagutta-percha endodonticsbusinessbiology.organism_classificationGeneral Dentistry
researchProduct

Weekly cisplatin with or without imatinib in advanced chordoma: A retrospective case-series analysis from the Italian Rare Cancers Network

2021

Background: To report on a retrospective case-series analysis of weekly cisplatin (wCDDP) as a single agent or combined with imatinib (wCDDP/I) in patients with advanced chordoma treated within the Italian Rare Cancer Network. Methods: Adult patients with a diagnosis of advanced, brachyury-positive chordoma, treated from April 2007 to October 2020 with wCDDP or wCDDP/I were retrospectively identified. Imatinib was withheld at the same time as wCDDP. Response according to Response Evaluation Criteria in Solid Tumors, overall survival (OS), and progression-free survival (PFS) were analyzed. Results: Thirty-three consecutive patients were identified (wCDDP as front-line n = 8 [24.2%]; wCDDP as…

AdultCancer Researchbone sarcomacisplatinsystemic treatmentchemotherapyDisease-Free SurvivalTreatment OutcomeOncologyimatinibImatinib MesylateHumansProspective StudieschordomaRetrospective Studies
researchProduct

Valutazione in vitro dell’affaticamento di strumenti rotanti in nichel-titanio

2012

Riassunto Obiettivo L’obiettivo di questo lavoro e quello di valutare, in vitro, la fatica ciclica di ProFile, K3 e Twisted File, strumenti rotanti in nichel-titanio, in canali radicolari simulati aventi angoli di curvatura di 45°, 60° e 90°. Materiali e metodi Per effettuare questo studio sono stati utilizzati: 18 file 25/.06 ProFile; 18 file 25/.06 K3; 18 file 25/.06 Twisted File. La resistenza a fatica ciclica degli strumenti rotanti Ni-Ti e stata testata ad angolazioni di 45°, 60° e 90° mediante un modello sperimentale creato specificatamente. Risultati e conclusioni Dall’analisi dei dati e emersa una buona resistenza alla fatica ciclica per quanto concerne le sistematiche ProFile e Twi…

PhysicsMedicine(all)nickel-titanium cycling fatigue analysisSettore MED/28 - Malattie OdontostomatologicheGeneral DentistryHumanitiesGiornale Italiano di Endodonzia
researchProduct

Preclinical and clinical evidence of activity of pazopanib in solitary fibrous tumour

2014

Abstract Background To explore the activity of pazopanib in solitary fibrous tumour (SFT). Patients and methods In a preclinical study, we compared the activity of pazopanib, sorafenib, sunitinib, regorafenib, axitinib and bevacizumab in a dedifferentiated-SFT (DSFT) xenotransplanted into Severe Combined Immunodeficiency (SCID) mice. Antiangiogenics were administered at their reported optimal doses when mean tumour volume (TV) was 80 mm3. Drug activity was assessed as TV inhibition percentage (TVI%). From May 2012, six consecutive patients with advanced SFT received pazopanib, on a national name-based programme. In one case sunitinib was administered after pazopanib failure. Results In the …

Chemotherapy; Pazopanib; Sarcoma; Solitary fibrous tumour; Sunitinib; Tyrosine kinase; Administration Oral; Adult; Aged; Angiogenesis Inhibitors; Animals; Antibodies Monoclonal Humanized; Antineoplastic Agents; Bevacizumab; Humans; Imidazoles; Indazoles; Indoles; MAP Kinase Signaling System; Male; Mice SCID; Middle Aged; Neoplasm Transplantation; Niacinamide; Phenylurea Compounds; Pyridines; Pyrimidines; Pyrroles; Receptor Platelet-Derived Growth Factor beta; Solitary Fibrous Tumors; Sulfonamides; Transplantation Heterologous; Vascular Endothelial Growth Factor Receptor-2; Cancer Research; Oncology; Medicine (all)OncologyMaleCancer ResearchIndolesAxitinibPyridinesPyridinemedicine.medical_treatmentSolitary fibrous tumourAdministration OralAngiogenesis InhibitorsMice SCIDPharmacologyPyrroleAntineoplastic Agentchemistry.chemical_compoundMiceSolitary Fibrous TumorChemotherapy; Pazopanib; Sarcoma; Solitary fibrous tumour; Sunitinib; Tyrosine kinase; Cancer Research; Oncology; Medicine (all)Transplantation HeterologouMonoclonalSunitinibHumanizedSulfonamidesHeterologousSunitinibMedicine (all)ImidazolesSarcomaMiddle AgedSorafenibPlatelet-Derived Growth Factor betaAxitinibBevacizumabOncologySolitary Fibrous TumorsAdministrationAngiogenesis InhibitorHumanmedicine.drugReceptorPhenylurea CompoundSorafenibOralAdultNiacinamidemedicine.medical_specialtyIndazolesBevacizumabMAP Kinase Signaling SystemTransplantation HeterologousAntineoplastic AgentsSulfonamideAntibodies Monoclonal HumanizedSCIDAntibodiesReceptor Platelet-Derived Growth Factor betaPazopanibInternal medicineRegorafenibmedicineAnimalsHumansChemotherapyPyrrolesImidazoleTyrosine kinaseAgedChemotherapyTransplantationAnimalbusiness.industryPhenylurea CompoundsPazopanibmedicine.diseaseChemotherapy; Pazopanib; Sarcoma; Solitary fibrous tumour; Sunitinib; Tyrosine kinase; Administration Oral; Adult; Aged; Angiogenesis Inhibitors; Animals; Antibodies Monoclonal Humanized; Antineoplastic Agents; Axitinib; Bevacizumab; Humans; Imidazoles; Indazoles; Indoles; MAP Kinase Signaling System; Male; Mice SCID; Middle Aged; Neoplasm Transplantation; Niacinamide; Phenylurea Compounds; Pyridines; Pyrimidines; Pyrroles; Receptor Platelet-Derived Growth Factor beta; Solitary Fibrous Tumors; Sorafenib; Sulfonamides; Sunitinib; Transplantation Heterologous; Vascular Endothelial Growth Factor Receptor-2Vascular Endothelial Growth Factor Receptor-2IndazolePyrimidinesPyrimidinechemistryIndolebusinessProgressive diseaseNeoplasm Transplantation
researchProduct

Doxorubicin plus dacarbazine (DTIC) in advanced solitary fibrous tumor (SFT): An Italian retrospective case series analysis.

2016

11042Background: The reported response rate to chemotherapy (CT) in SFT is low both with anthracycline-based regimens ( ≤ 20%) and with trabectedin ( < 10%). DTIC can be active. We report on the co...

OncologyCancer Researchmedicine.medical_specialtyChemotherapySolitary fibrous tumorSeries (stratigraphy)Anthracyclinebusiness.industrymedicine.medical_treatmentfungifood and beverages.medicine.diseaseOncologyInternal medicineMedicineDoxorubicinDacarbazine - DTICbusinessTrabectedinmedicine.drugJournal of Clinical Oncology
researchProduct

FAP-related desmoid tumours treated with low dose chemotherapy: Results from a multicentre retrospective analysis.

2018

11556Background: Desmoid tumours (DTs) are monoclonal neoplasms with fibroblastic-myofibroblastic differentiation and they represent the most common extra-intestinal manifestation of familial adeno...

0301 basic medicineOncologyCancer Researchmedicine.medical_specialtybusiness.industrybody regions03 medical and health sciences030104 developmental biology0302 clinical medicineOncologyLow-dose chemotherapy030220 oncology & carcinogenesisInternal medicineMonoclonalmedicineRetrospective analysisDesmoid tumoursbusinessJournal of Clinical Oncology
researchProduct

Human umbilical cord expresses several vasoactive peptides involved in the local regulation of vascular tone: protein and gene expression of Orphanin…

2011

Full-term human umbilical cord contains three blood vessels: two arteries coiled around a vein and surrounded by Wharton&amp;#8217;s jelly, a mucous tissue with few mesenchymal stromal cells and abundant extracellular matrix. Umbilical vessels lack innervations, thus endothelial cells must play a role in the control of blood flow. The aim of this study was to investigate in human umbilical cord the expression of five peptides that could be involved in the regulation of vascular tone: Orphanin FQ, Oxytocin, Atrial Natriuretic Peptide (ANP), endothelial Nitric Oxide Synthase (eNOS) and inducible Nitric Oxide Synthase (iNOS). The expression of these molecules in full-term human umbilical cord …

Settore BIO/17 - IstologiaMalemedicine.medical_specialtyHistologyEndotheliumNitric Oxide Synthase Type IIINitric Oxide Synthase Type IIhuman umbilical cord Orphanin Oxytocin ANP eNOS iNOSOxytocinUmbilical cordPathology and Forensic MedicineUmbilical CordAtrial natriuretic peptideEnosInternal medicineWharton's jellyMedicineAnimalsHumanslcsh:QH573-671Rats Wistarbiologylcsh:Cytologybusiness.industryReverse Transcriptase Polymerase Chain ReactionGeneral MedicineOrphaninbiology.organism_classificationImmunohistochemistryRatsiNOSEndothelial stem cellNitric oxide synthaseEndocrinologymedicine.anatomical_structureGene Expression RegulationOpioid Peptideshuman umbilical cordeNOScardiovascular systembiology.proteinBlood VesselsFemalebusinessANPhormones hormone substitutes and hormone antagonistsAtrial Natriuretic FactorBlood vesselFolia histochemica et cytobiologica
researchProduct

The use of pegylated liposomal doxorubicin (PLD) in association with weekly paclitaxel as second line therapy in metastatic bladder carcinoma: final …

2010

bladder cancer
researchProduct